Lite Strategy (LITS) Total Current Liabilities (2011 - 2026)
Lite Strategy (LITS) posted quarterly Total Current Liabilities of $952000.0 for Q1 2026, down 23.1% year-over-year from $1.2 million in Q1 2025, and down 12.42% quarter-over-quarter from $1.1 million in Q4 2025.
Lite Strategy (LITS) Total Current Liabilities (2011 - 2026) Analysis & Trends
Lite Strategy's Total Current Liabilities history runs 16 years deep, the most recent figure standing at $952000.0 for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 23.1% year-over-year to $952000.0; the TTM figure through Mar 2026 stood at $952000.0 (down 23.1% YoY), while the FY2025 annual figure was $1.4 million, down 83.79% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $952000.0, down from $1.1 million in the prior quarter.
- The five-year high for Total Current Liabilities was $24.4 million in Q2 2022, with the low at $952000.0 in Q1 2026.
- The 5-year median for Total Current Liabilities is $8.4 million (2024), against an average of $10.8 million.
- The sharpest annual moves came in 2022 and 2025: Total Current Liabilities grew 20.94% in 2022, then slumped 87.13% in 2025.
- Lite Strategy's Total Current Liabilities stood at $22.7 million in 2022, then sank by 64.52% to $8.0 million in 2023, then sank by 71.55% to $2.3 million in 2024, then tumbled by 52.47% to $1.1 million in 2025, then dropped by 12.42% to $952000.0 in 2026.
- Business Quant data shows LITS's Total Current Liabilities at $952000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.54 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 86.13 Bn | 78.13 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 65.58 Bn | 60.40 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 42.18 Bn | 37.08 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 27.97 Bn | 9.58 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.55 Bn | 26.39 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | 630.93 Mn |
| 10 | Lite Strategy | 36.96 Mn | 29.42 Mn | - | 952,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 952,000.00 |
| Dec 31, 2025 | 1.09 Mn |
| Sep 30, 2025 | 1.07 Mn |
| Jun 30, 2025 | 1.35 Mn |
| Mar 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 2.29 Mn |
| Sep 30, 2024 | 2.87 Mn |
| Jun 30, 2024 | 8.36 Mn |
| Mar 31, 2024 | 9.62 Mn |
| Dec 31, 2023 | 8.04 Mn |
| Sep 30, 2023 | 8.56 Mn |
| Jun 30, 2023 | 20.34 Mn |
| Mar 31, 2023 | 23.62 Mn |
| Dec 31, 2022 | 22.65 Mn |
| Sep 30, 2022 | 23.44 Mn |
| Jun 30, 2022 | 24.44 Mn |
| Mar 31, 2022 | 23.96 Mn |
| Dec 31, 2021 | 22.67 Mn |
| Sep 30, 2021 | 20.84 Mn |
| Jun 30, 2021 | 20.21 Mn |